Administration of BCG cell wall skeleton into malignant effusions: Toxic and therapeutic effects

S. P. Richman, Evan M Hersh, J. U. Gutterman, G. N. Hortobagyi, G. R. Blumenschein, A. Rios, E. Ribi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Thirty-nine patients wqith 40 refractory malignant effusions (26 pleural and 14 peritoneal) were treated locally with a nonviable mycobacterial vaccine. The vaccine was administered into the effusion and consisted of BCG cell wall skeleton and trehalose dimycolate attached to oil microdroplets. A dose range of 150-3000 μg was tested. The overall response rate was 44.0% (complete response [CR] plus partial response [PR]) and was not clearly dose-related. The response rates for each site were 13.6% (CR) and 31.8% (PR) for pleural effusions and 33.3% (CR) and 8.3% (PR) for peritoneal effusions. Toxic effects consisted of fever (40%), serosal pain (37.5%), and increased effusion (27.5%) and were not clearly dose-related. Gastrointestinal toxic effects were seen in 50% of patients treated for peritoneal effusions. Response correlated with prior exposure to BCG vaccine or tuberculosis, and with a febrile response to vaccine administration. This vaccine has a therapeutic effect on both pleural and peritoneal effusions.

Original languageEnglish (US)
Pages (from-to)383-387
Number of pages5
JournalCancer Treatment Reports
Volume65
Issue number5-6
StatePublished - 1981
Externally publishedYes

Fingerprint

Cell Wall Skeleton
Poisons
Therapeutic Uses
Mycobacterium bovis
Ascitic Fluid
Vaccines
Pleural Effusion
Fever
Cord Factors
Malignant Pleural Effusion
BCG Vaccine
Oils
Tuberculosis
Pain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Richman, S. P., Hersh, E. M., Gutterman, J. U., Hortobagyi, G. N., Blumenschein, G. R., Rios, A., & Ribi, E. (1981). Administration of BCG cell wall skeleton into malignant effusions: Toxic and therapeutic effects. Cancer Treatment Reports, 65(5-6), 383-387.

Administration of BCG cell wall skeleton into malignant effusions : Toxic and therapeutic effects. / Richman, S. P.; Hersh, Evan M; Gutterman, J. U.; Hortobagyi, G. N.; Blumenschein, G. R.; Rios, A.; Ribi, E.

In: Cancer Treatment Reports, Vol. 65, No. 5-6, 1981, p. 383-387.

Research output: Contribution to journalArticle

Richman, SP, Hersh, EM, Gutterman, JU, Hortobagyi, GN, Blumenschein, GR, Rios, A & Ribi, E 1981, 'Administration of BCG cell wall skeleton into malignant effusions: Toxic and therapeutic effects', Cancer Treatment Reports, vol. 65, no. 5-6, pp. 383-387.
Richman SP, Hersh EM, Gutterman JU, Hortobagyi GN, Blumenschein GR, Rios A et al. Administration of BCG cell wall skeleton into malignant effusions: Toxic and therapeutic effects. Cancer Treatment Reports. 1981;65(5-6):383-387.
Richman, S. P. ; Hersh, Evan M ; Gutterman, J. U. ; Hortobagyi, G. N. ; Blumenschein, G. R. ; Rios, A. ; Ribi, E. / Administration of BCG cell wall skeleton into malignant effusions : Toxic and therapeutic effects. In: Cancer Treatment Reports. 1981 ; Vol. 65, No. 5-6. pp. 383-387.
@article{3ff3a808f8814045ba2fdaf7804a6bd9,
title = "Administration of BCG cell wall skeleton into malignant effusions: Toxic and therapeutic effects",
abstract = "Thirty-nine patients wqith 40 refractory malignant effusions (26 pleural and 14 peritoneal) were treated locally with a nonviable mycobacterial vaccine. The vaccine was administered into the effusion and consisted of BCG cell wall skeleton and trehalose dimycolate attached to oil microdroplets. A dose range of 150-3000 μg was tested. The overall response rate was 44.0{\%} (complete response [CR] plus partial response [PR]) and was not clearly dose-related. The response rates for each site were 13.6{\%} (CR) and 31.8{\%} (PR) for pleural effusions and 33.3{\%} (CR) and 8.3{\%} (PR) for peritoneal effusions. Toxic effects consisted of fever (40{\%}), serosal pain (37.5{\%}), and increased effusion (27.5{\%}) and were not clearly dose-related. Gastrointestinal toxic effects were seen in 50{\%} of patients treated for peritoneal effusions. Response correlated with prior exposure to BCG vaccine or tuberculosis, and with a febrile response to vaccine administration. This vaccine has a therapeutic effect on both pleural and peritoneal effusions.",
author = "Richman, {S. P.} and Hersh, {Evan M} and Gutterman, {J. U.} and Hortobagyi, {G. N.} and Blumenschein, {G. R.} and A. Rios and E. Ribi",
year = "1981",
language = "English (US)",
volume = "65",
pages = "383--387",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5-6",

}

TY - JOUR

T1 - Administration of BCG cell wall skeleton into malignant effusions

T2 - Toxic and therapeutic effects

AU - Richman, S. P.

AU - Hersh, Evan M

AU - Gutterman, J. U.

AU - Hortobagyi, G. N.

AU - Blumenschein, G. R.

AU - Rios, A.

AU - Ribi, E.

PY - 1981

Y1 - 1981

N2 - Thirty-nine patients wqith 40 refractory malignant effusions (26 pleural and 14 peritoneal) were treated locally with a nonviable mycobacterial vaccine. The vaccine was administered into the effusion and consisted of BCG cell wall skeleton and trehalose dimycolate attached to oil microdroplets. A dose range of 150-3000 μg was tested. The overall response rate was 44.0% (complete response [CR] plus partial response [PR]) and was not clearly dose-related. The response rates for each site were 13.6% (CR) and 31.8% (PR) for pleural effusions and 33.3% (CR) and 8.3% (PR) for peritoneal effusions. Toxic effects consisted of fever (40%), serosal pain (37.5%), and increased effusion (27.5%) and were not clearly dose-related. Gastrointestinal toxic effects were seen in 50% of patients treated for peritoneal effusions. Response correlated with prior exposure to BCG vaccine or tuberculosis, and with a febrile response to vaccine administration. This vaccine has a therapeutic effect on both pleural and peritoneal effusions.

AB - Thirty-nine patients wqith 40 refractory malignant effusions (26 pleural and 14 peritoneal) were treated locally with a nonviable mycobacterial vaccine. The vaccine was administered into the effusion and consisted of BCG cell wall skeleton and trehalose dimycolate attached to oil microdroplets. A dose range of 150-3000 μg was tested. The overall response rate was 44.0% (complete response [CR] plus partial response [PR]) and was not clearly dose-related. The response rates for each site were 13.6% (CR) and 31.8% (PR) for pleural effusions and 33.3% (CR) and 8.3% (PR) for peritoneal effusions. Toxic effects consisted of fever (40%), serosal pain (37.5%), and increased effusion (27.5%) and were not clearly dose-related. Gastrointestinal toxic effects were seen in 50% of patients treated for peritoneal effusions. Response correlated with prior exposure to BCG vaccine or tuberculosis, and with a febrile response to vaccine administration. This vaccine has a therapeutic effect on both pleural and peritoneal effusions.

UR - http://www.scopus.com/inward/record.url?scp=0019493395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019493395&partnerID=8YFLogxK

M3 - Article

C2 - 7237463

AN - SCOPUS:0019493395

VL - 65

SP - 383

EP - 387

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5-6

ER -